181 related articles for article (PubMed ID: 11205628)
21. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
22. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
[TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
van Delden C
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
[TBL] [Abstract][Full Text] [Related]
24. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e171-5. PubMed ID: 20471883
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
26. [On the way to optimal Pseudomonas aeruginosa bacteriemia therapy].
Cobo Reinoso J; Moreno Guillén S
Rev Clin Esp; 2004 Sep; 204(9):445-7. PubMed ID: 15388016
[No Abstract] [Full Text] [Related]
27. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
29. Frequency of Blood Culture Isolates and their Antibiogram in a Teaching hospital.
Shrestha S; Amatya R; Shrestha RK; Shrestha R
JNMA J Nepal Med Assoc; 2014; 52(193):692-6. PubMed ID: 26905550
[TBL] [Abstract][Full Text] [Related]
30. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
31. Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.
Lynch JP; Zhanel GG; Clark NM
Semin Respir Crit Care Med; 2017 Jun; 38(3):326-345. PubMed ID: 28578556
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
33. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.
Siegman-Igra Y; Ravona R; Primerman H; Giladi M
Int J Infect Dis; 1998; 2(4):211-5. PubMed ID: 9763504
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
Suárez C; Peña C; Tubau F; Gavaldà L; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
J Infect; 2009 Apr; 58(4):285-90. PubMed ID: 19297028
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa.
Aliaga L; Mediavilla JD; Llosá J; Miranda C; Rosa-Fraile M
Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):871-4. PubMed ID: 11152313
[TBL] [Abstract][Full Text] [Related]
36. Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy.
McCarthy K
Semin Respir Crit Care Med; 2015 Feb; 36(1):44-55. PubMed ID: 25643270
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia.
McCarthy KL; Paterson DL
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):152-157. PubMed ID: 28366610
[TBL] [Abstract][Full Text] [Related]
38. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
39. The changing epidemiology of bacteremia in neutropenic children with cancer.
Aquino VM; Pappo A; Buchanan GR; Tkaczewski I; Mustafa MM
Pediatr Infect Dis J; 1995 Feb; 14(2):140-3. PubMed ID: 7746697
[TBL] [Abstract][Full Text] [Related]
40. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.
Marra AR; Pereira CA; Gales AC; Menezes LC; Cal RG; de Souza JM; Edmond MB; Faro C; Wey SB
Antimicrob Agents Chemother; 2006 Jan; 50(1):388-90. PubMed ID: 16377720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
